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undergoing 54 AlloSCTs where donors and/or recipients were
CMV seropositive. CMV seronegative donors and recipient pairs
received leukodepleted blood products only. Prophylaxis spanned
frommyeloid recovery (ANC 750/mm3) until day100. Patients
were: M:F 29:21; mean age 8 years (0.8–20 years); donor sources:
24 HLA matched related bone marrow (BM) or peripheral blood
stem cells (PBSC), 2 related cord blood (CB), 3 MUDs, and 25
unrelated CB. HLA matching for related PBSC/BM included
twenty 6/6 and four 5/6; related CB included one 6/6 and one 5/6;
unrelated adult donors included one 10/10 and two 9/10; unrelated
CBT included two 6/6, eight 5/6 and ﬁfteen 4/6. Twenty one
(39%) patients received full intensity conditioning and 33 (61%)
patients received reduced intensity conditioning. GVHD prophy-
laxis included tacrolimus/mycophenolate mofetil as we have pre-
viously described (Osunkwo/Cairo BBMT. 2004). Mean nucleated
and CD34 cell counts were 8.1  4.9  108/kg and 5.4  2.4 
106/kg, respectively, for BM/PBSC; 4.7  2.7  107/kg and 2.6 
2.0  105/kg, respectively, for CB. Despite a 39% probability of
grade II-IV acute GVHD, no patient developed systemic CMV
disease. Twenty eight percent had grade III/IV hematological
toxicity possibly secondary to Gan/Fos. Patients developed tran-
sient nephrotoxicity and electrolyte imbalances secondary to Gan/
Fos, however no patient developed permanent renal dysfunction
and all patients were on at least 2 other concomitant nephrotoxic
drugs. Probability of 1-year overall survival was 69%. Alternate day
Gan/Fos in AlloSCT recipients where recipient and/or donor is
seropositive, especially in unrelated donor recipients, appears to be
tolerable and effective in preventing CMV systemic disease. A
future randomized trial will be required to determine if this ap-
proach not only reduces systemic CMV disease but also reduces
hematological toxicity of daily ganciclovir.
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EFFICACY OF POSACONAZOLE (POS) VS STANDARD THERAPY AND
SAFETY OF POS IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
RECIPIENTS VS OTHER PATIENTS WITH ASPERGILLOSIS
van Burik, J.-A.1, Perfect, J.2, Louie, A.3, Graybill, J.R.4,
Pedicone, L.5, Raad, I.I.6 1. University of Minnesota, Minneapolis, MN;
2. Duke University Medical Center, Durham, NC; 3. Ordway Research
Institute, Albany, NY; 4. University of Texas Health Sciences Center,
San Antonio, TX; 5. Schering-Plough Research Institute, Kenilworth,
NJ; 6. M.D. Anderson Cancer Center, Houston, TX.
Introduction: Antifungal therapy response is typically low in
HSCT recipients with aspergillosis. We compared (1) outcomes in
POS-treated HSCT and non-HSCT recipients with aspergillosis
with those of external controls receiving other antifungal therapy; (2)
safety of POS in HSCT and non-HSCT recipients with aspergillosis.
Methods: Patients with invasive fungal infections, including HSCT
recipients, who were intolerant of or refractory to other antifungal
therapy received oral POS 800 mg/d in divided doses in a prospective,
open-label, multicenter study. An external control group mainly in-
cluded patients concurrently hospitalized at the same institutions with
similar baseline characteristics receiving other therapy (amphotericin
B [any formulation], itraconazole, and/or investigational agents when
the study was conducted [eg, voriconazole and echinocandins]) as
salvage treatment. A blinded data review committee assessed eligibil-
ity, diagnosis, and outcome of all patients. Results: One hundred
seven of 330 patients in the POS group and 86 of 279 in the control
group had aspergillosis. Overall response was 42% (45/107) in the
POS group and 26% (22/86) in the control group (P .006; OR 4.06
[95% CI 1.5–11.04]). POS was associated with signiﬁcant survival
beneﬁt vs other therapy (P  .0003). In patients with neutropenia at
baseline (500/l), POS was associated with 24% response vs 8% in
controls. Percentage of responders was lower in HSCT recipients
than in the overall populations of both groups but was greater in
POS-treated vs control HSCT recipients. Response in POS-treated
autologous HSCT recipients was higher than in controls (Table 1) .
Response in HSCT recipients by type of leukemia is shown in the
Table. Most common adverse events (AEs) related to POS were
nausea (HSCT 11%; non-HSCT 13%), vomiting (HSCT 4%; non-
HSCT 6%), and rash (HSCT 2%; non-HSCT 6%). Convulsions
(n  2) and increased hepatic enzymes (n  2) were serious AEs in
HSCT recipients considered by the investigator to be at least possibly
related to POS. POS was well tolerated. Conclusions: There was a
signiﬁcantly greater global response rate and survival advantage in
POS-treated patients with aspergillosis vs external controls receiving
other antifungal therapy. In HSCT recipients, there was a greater
response rate in the POS group vs the control group, suggesting POS
as an option for HSCT recipients with fungal infections refractory to
other therapy. Safety of POS was similar in HSCT and non-HSCT
recipients (Table1).
Table 1.
POS External Control
Total,
n
Responders,
n (%)
Total,
n
Responders,
n (%)
HSCT status
Any HSCT 55 21 (38.2) 38 7 (18.4)
Allogeneic 48 15 (31.3) 34 7 (20.6)
Autologous 7 6 (85.7) 4 0 (0)
Type of
leukemia
Acute
myelogenous 14 5 (36) 5 1 (20)
Acute
lymphocytic 5 1 (20) 6 3 (50)
Chronic
myelogenous 9 6 (67) 7 0 (0)
Chronic
lymphocytic 4 0 (0) 2 1 (50)
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URSODIOL PROPHYLAXIS AGAINST HEPATIC VENO-OCCLUSIVE DIS-
EASE IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Zirakzadeh, A.1, Montori, V.1, Imran, H.1, Litzow, M.1, Kumar, S.1
Mayo College of Medicine, Rochester, MN.
Hepatic veno-occlusive disease (VOD) is a well-recognized compli-
cation of hematopoietic stem cell transplantation (HSCT). Ursodiol
has been studied as a prophylactic agent against this condition with
varying success. We performed a systematic review and meta-analysis
of the existing literature to assess the effectiveness of ursodiol in
preventing VOD in patients undergoingHSCT.We conducted com-
puterized and hand searches of ursodiol, hepatic VOD, and variations
of the two terms. We then selected those randomized trials and
observational studies which compared the incidence of VOD in
HSCT patients receiving ursodiol versus control. The outcome data
from the eligible studies were pooled and summarized (Table 1). We
also preformed an a priori subgroup analysis based on study type
(observational vs randomized clinical trial), type of conditioning reg-
imen used (busulfan vs total body irradiation based), time from urso-
diol initiation to transplant, type of transplant (allogeneic vs autolo-
gous) and different diagnostic criteria for VOD (Seattle criteria vs
modiﬁed Seattle criteria. Overall, we found that ursodiol prophylaxis
decreased the risk of VOD (pooled OR 0.33, 95% CI 0.12, 0.90). All
subgroups showed beneﬁted from ursodiol use; however wide conﬁ-
dence intervals indicate imprecision in the estimate of this beneﬁt.
Also, there was no statistically signiﬁcant difference in survival when
comparing subgroups: clinical trial versus observational study, P 
.89; busulfan vs total body irradiation, P .64; Seattle versus modiﬁed
Seattle criteria, P .36.Wewere unable to perform statistical analysis
on the type of transplant (allogeneic vs autologous), and time from
ursodiol initiation to transplant. Finally, despite our a priori subgroup
analysis, unexplained differences in results (ie, heterogeneity) contin-
ued to exist between studies. These differences were only partially
explained by analysis based on diagnostic criteria. I2 (the test statistic
used to describe heterogeneity) decreased to 0% for the modiﬁed
Seattle criteria group but remained high (76%) for the Seattle criteria
group. This review supports the assertion that ursodiol decreases the
incidence of VOD in patients receiving HSCT. However, unex-
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plained heterogeneity weakens our inference (Table1).
Table 1. Estimate of Risk for Developing VOD
Subgroup
Investigations
Contributing data
OR with 95%
Confidence Interval I2
All trials Ohashi, Ruutu, Essell 92,
and 98, Carerras,
Thompson
0.33 [0.12, 0.90] 67.6%
Clinical trial Ohashi, Ruutu, Essell 98 0.30 [0.03, 2.80] 70.5%
Observational study Thompson, Carerras,
Essell 92
0.36 [0.11, 1.23] 80.4%
Busulfan conditioned
patients
Essell 92, Essell 98,
Ohashi
0.19 [0.06, 0.59] 41%
TBI conditioned patients Ohashi, Ruutu 0.37 [0.03, 4.84] 67%
Seattle criteria Essell 92, Essell 98,
Ruutu, Thompson
0.40 [0.12, 1.37] 76%
modified Seattle criteria Carerras, Ohashi 0.17 [0.04, 0.64] 0%
Allogeneic transplant
recipients
Essell 92, Essell 98,
Ohashi, Ruutu,
Thompson
0.33 [0.11, 0.99] 73.7%
I2 represents the precentage of unexplained heterogeneity.
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A RETROSPECTIVE ANALYSIS OF THE IMPACT OF ERYTHROPOEITIC
GROWTH FACTOR UTILIZATION ON TRANSFUSION REQUIREMENTS IN
PATIENTS WITH AL AMYLOIDOSIS UNDERGOING AUTOLOGOUS SCT
Baribeault, D.M.1, Shah, B.1, Finn, K.T.1, Seldin, D.C.1, Quillen, K.1,
Sanchorawala, V.1 Boston Medical Center, Boston, MA.
Introduction: The beneﬁt of the addition of erythropoietin-
derived growth factors (EPOs) to neutrophil growth factors to
hasten engraftment and decrease transfusion requirements in pa-
tients undergoing hematopoietic stem cell transplantation is un-
certain. We previously reported the equivalence between erythro-
poetin alfa and long-acting darbepoetin alfa in patients with AL
amyloidosis undergoing autologous stem cell transplantation
(ASCT). To further evaluate EPOs in this patient population, we
examined the time to neutrophil engraftment and transfusion re-
quirements in all patients undergoing ASCT for AL amyloidosis
over a 10 year period. Methods: A retrospective review was con-
ducted of all patients undergoing ASCT between July 1994 and
July 2005. Three groups were compared. Group A consisted of
patients treated with darbepoetin alfa at 200 mcg weekly (n  64),
Group B consisted of patients treated with epoetin alfa at either
150 u/kg thrice weekly or 40,000 units weekly (n  151), and
Group C consisted of those patients not treated with EPOs (n 
161). All groups were treated with GCSF to promote neutrophil
engraftment. Primary endpoints evaluated were mean number of
units of PRBCs transfused and time to neutrophil engraftment. A
secondary endpoint was the proportion of patients requiring PRBC
transfusion. Groups were stratiﬁed by intensity of conditioning
regimen as well as for life-threatening bleeding events and re-
analyzed. A nonparametric analysis of variance was conducted
utilizing the Kruskal-Wallis test with plans for a Dunn comparison
of all three groups in the event of a P value  0.05. Results: The
mean number of PRBC units transfused was 3.23, 4.5, and 3.92 for
Groups A, B, and C, respectively; P  .1591. The mean number of
days to engraftment was 9.87, 10.3, and 10.4 for the groups; P 
.0956. When life threatening bleeding events were excluded, there
was still no signiﬁcant difference, P  .12. In the subgroup of
patients receiving the highest dose (200 mg/m2) of melphalan, the
proportion of patients not requiring RBC transfusion was higher in
the group receiving EPOs (38% versus 23%, P  .0512, 2).
Discussion: In this analysis, we were unable to demonstrate a
beneﬁt for EPOs in the entire patient group, which is heteroge-
nous in terms of chemotherapy dosing and bleeding complications.
However, when we examined those patients receiving the highest
dose of chemotherapy, an increase in the percentage of patients not
requiring RBC transfusion support was seen.
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MELPHALAN-INDUCED SEVERE ORAL MUCOSITIS IS PREVENTED BY
ORAL CRYOTHERAPY IN AUTOLOGOUS HEMATOPOIETIC CELL TRANS-
PLANT RECIPIENTS
Rimkus, C.F.1, Waller, P.1, Oliver, D.A.1, Richart, J.M.1,
Pincus, S.M.1 Saint Louis University, St. Louis, MO.
Background: Oral mucositis is an expected complication of high
dose mephalan chemotherapy due to its cytotoxic effects. Severe
mucositis leads to complications of severe pain requiring narcotic
management, difﬁculty or inability to eat and take oral medica-
tions, and prolonged hospital stays. Melphalan has a very short
plasma half-life making it an ideal candidate for cryotherapy inter-
vention.
Objective: Primary objective is to evaluate whether the cryo-
therapy intervention will reduce mucositis in patients receiving
high dose melphalan compared to historical controls. Secondary
objectives included determining the tolerance of the procedure and
comparing the need for intravenous narcotics to historical controls.
Methods:The program assessed a modiﬁed version of cytotherapy
intervention protocols reported previously by two institutions.
Patients and staff were given written and verbal instructions de-
scribing the oral cryotherapy intervention. The procedure in-
cluded holding cold medium (ice, popsicle, cold ﬂuid) in the mouth
beginning 10 minutes before the melphalan infusion and continu-
ing until 1 hour after the infusion was completed. Results: Con-
secutive patients (multiple myeloma 18, NHL 13, other 3) being
conditioned with melphalan were eligible. The cryotherapy inter-
vention was used 04/04&ndash09/05, (n  20). A retrospective
review of previous consecutive transplants provided the melphalan
matched controls (03/02–03/04), n  14. Most (90%) of the
patients were able to complete the entire procedure for oral cryo-
therapy. Two patient (10%) intermittently followed the procedure
because they felt too full from drinking cold ﬂuid. Subsequently,
cold ﬂuid has been eliminated as an option for treatment. Forty-
three percent of historical controls had severe mucositis compared
to none of the patients who received cryotherapy (Table). Addi-
tionally, a dramatic difference in the amount of opiate used was
noted. In the historical control group 47% of patients required IV
PCA (cummulative dose MSO4 937mg and Fentanyl 11,850 mcg)
compared to 10% in the cryotherapy group (cumulative 68 mg
MSO4) (Table 1). Summary: Cryotherapy was well tolerated and
appeared to decrease mucositis in high dose melphalan recipients.
Additionally, there was a decrease in IV pain medication use re-
sulting in less overall morbidity.
Table 1. Mucositis in Melphalan Recipients
Intervention Patients None/Mild Moderate Severe
No cryotherapy 14 6 (43%) 2 (14%) 6 (43%)*
Cryotherapy 20 17 (85%) 3 (15%) 0
*Two intubated for airway protection.
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PHASE III TRIAL OF VALACYCLOVIR FOR THE PREVENTION OF SHIN-
GLES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Klein, A.K.1, DesJardins, J.1, Koc, Y.2, Miller, K.B.3, Schenkein, D.S.1,
Sprague, K.S.1, Snydman, D.R.1 1. Tufts-New England Medical Cen-
ter, Boston, MA; 2. Hacettepe University, Ankara, Turkey; 3. Beth
Israel Deaconess Medical Center, Boston, MA.
Despite advances in antiviral therapy, reactivation of latent vari-
cella-zoster virus (VZV) infections remains a signiﬁcant cause of
morbidity following stem cell transplantation (SCT). Twenty-ﬁve
percent or more of patients undergoing SCT will reactivate VZV
in the form of zoster (shingles) within the ﬁrst year after transplant.
Short course (6–12 months) prophylactic therapy with acyclovir
has been shown effective, but compliance with administration up to
5 times daily has been problematic, and outbreaks resumed follow-
ing completion. We undertook a phase III, randomized, double-
blind, placebo-controlled trial of valacyclovir (VACV, 1000 mg
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